Evidence map›Paper›PMID 28515464›Full record

ArticleScientific reports2017

Systems Immunology of Diabetes-Tuberculosis Comorbidity Reveals Signatures of Disease Complications.

Cesar A Prada-Medina, Kiyoshi F Fukutani, Nathella Pavan Kumar, Leonardo Gil-Santana, Subash Babu, Flávio Lichtenstein, Kim West, Shanmugam Sivakumar, Pradeep A Menon, Vijay Viswanathan and 3 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04208789 (Artificial Neural Network as Diagnostic Tools For Rifampicin-Resistant Tuberculosis In Indonesia), which is not on this map. Cited by 86 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 2 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04208789 completednot on this mapstarted 2020, after this paper: background citation

Artificial Neural Network as Diagnostic Tools For Rifampicin-Resistant Tuberculosis In Indonesia: A Predictive Model Study and Economic Evaluation

TypeobservationalSponsorHasanuddin UniversityRan2020 to 2020Enrolled524ConditionsMDR Tuberculosis, Resistance to Tuberculostatic DrugsArmsRapid Molecular Drug-Resistant Tuberculosis Test, Artificial Intelligent Model, Drug Susceptibility Test
3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 2 syntheses or guidelines pooled it, 123 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Molecular Epidemiology ofMicroorganisms · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Tuberculosis and Increased Incidence of Cardiovascular Disease: Cohort Study Using United States and United Kingdom Health Records.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 3 countries.

Cesar A Prada-MedinaDepartment of Pathophysiology and Toxicology, School of Pharmaceutical Sciences, University of São Paulo, 05508, São Paulo, Brazil.
Kiyoshi F FukutaniLaboratório de Imunoparasitologia, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.ORCID 0000-0003-2223-0918
Nathella Pavan KumarNational Institutes of Health- NIRT - International Center for Excellence in Research, Chennai, India.
Leonardo Gil-SantanaUnidade de Medicina Investigativa, Laboratório Integrado de Microbiologia e Imunorregulação, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Subash BabuNational Institutes of Health- NIRT - International Center for Excellence in Research, Chennai, India.
Flávio LichtensteinDepartment of Pathophysiology and Toxicology, School of Pharmaceutical Sciences, University of São Paulo, 05508, São Paulo, Brazil.
Kim WestDepartment of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
Shanmugam SivakumarNational Institute for Research in Tuberculosis, Chennai, India.
Pradeep A MenonNational Institute for Research in Tuberculosis, Chennai, India.
Vijay ViswanathanProf. M. Viswanathan Diabetes Research Center, Chennai, India.
Bruno B AndradeUnidade de Medicina Investigativa, Laboratório Integrado de Microbiologia e Imunorregulação, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Helder I NakayaDepartment of Pathophysiology and Toxicology, School of Pharmaceutical Sciences, University of São Paulo, 05508, São Paulo, Brazil. hnakaya@usp.br.
Hardy KornfeldDepartment of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America. Hardy.Kornfeld@umassmed.edu.
Universidade de São Paulo · BRInternational Centers for Excellence in Research · INNational Institute of Research in Tuberculosis · INUniversity of Massachusetts Chan Medical School · USFundação Oswaldo Cruz · BRFundo Brasil · BRIndia Diabetes Research Foundation · INVanderbilt University · US

Funding

India International Center for Excellence in ResearchZIAAI001065 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI NUTMAN, THOMAS · 2009 to 2025
$19.0M
6 · The paper itself

Abstract

Comorbid diabetes mellitus (DM) increases tuberculosis (TB) risk and adverse outcomes but the pathological interactions between DM and TB remain incompletely understood. We performed an integrative analysis of whole blood gene expression and plasma analytes, comparing South Indian TB patients with and without DM to diabetic and non-diabetic controls without TB. Luminex assay of plasma cytokines and growth factors delineated a distinct biosignature in comorbid TBDM in this cohort. Transcriptional profiling revealed elements in common with published TB signatures from cohorts that excluded DM. Neutrophil count correlated with the molecular degree of perturbation, especially in TBDM patients. Body mass index and HDL cholesterol were negatively correlated with molecular degree of perturbation. Diabetic complication pathways including several pathways linked to epigenetic reprogramming were activated in TBDM above levels observed with DM alone. Our data provide a rationale for trials of host-directed therapies in TBDM, targeting neutrophilic inflammation and diabetic complication pathways to address the greater morbidity and mortality associated with this increasingly prevalent dual burden of communicable and non-communicable diseases.

Indexed as

Diabetes ComplicationsImmunityBiomarkersComorbidityComputational BiologyCytokinesDiabetes MellitusDisease SusceptibilityFemaleGene Expression ProfilingHumansIndiaMaleProteomeProteomicsPublic Health SurveillanceBiomarkersCytokinesProteome

Identifiers

PMID28515464
PMCPMC5435727
OpenAlexW2613180822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.